Clinical evaluation company The IMA Group (IMA) revealed on Tuesday the completion of the acquisition of Diagnostics Research Group (DXRG) in San Antonio, Texas for an undisclosed amount.
Diagnostics Research Group (DXRG) reportedly provides expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies and pulmonary and fatty liver diseases.
Following closing, DXRG will continue to operate under its current name, with key leadership, investigators and staff remaining in place.
The acquisition which marks IMA's fourth this year adds to its growing Clinical Research Division and aligns with its mission to reach people everywhere as it partners with its sponsors to develop safe and effective new treatments. In addition it extends its access to diverse patient populations and its expansion into the southwestern US.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children